BOTULINUM VACCINE BIVALENT 2.5 ML DOSE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

botulinum vaccine bivalent 2.5 ml dose

csl limited - clostridium botulinum type d toxoid | clostridium botulinum type c - immunotherapy - cattle | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | heifer | steer - vaccines and antisera | brown snake bite | cheesy gland | enterotoxaemia | tetanus

BOCOUTURE 100 units powder for solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

bocouture 100 units powder for solution for injection

merz pharmaceuticals gmbh - clostridium botulinum neurotoxin type a (150kd), free of complexing proteins - powder for solution for injection - 100 unit(s) - botulinum toxin

BOCOUTURE 50 units powder for solution for injection Ireland - English - HPRA (Health Products Regulatory Authority)

bocouture 50 units powder for solution for injection

merz pharmaceuticals gmbh - clostridium botulinum neurotoxin type a (150kd), free of complexing proteins - powder for solution for injection - 50 unit(s) - botulinum toxin

GLANVAC 6S VACCINE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

glanvac 6s vaccine

zoetis australia pty ltd - selenium as sodium selenate; clostridium chauvoei - formol culture; clostridium novyi type b - toxoid; clostridium perfringens type d toxoid; clostridium septicum - toxoid; clostridium tetani - toxoid; corynebacterium pseudotuberculosis (ovis) - toxoid; thiomersal - misc. vaccines or anti sera - selenium as sodium selenate mineral-selenium active 1.0 mg/ml; clostridium chauvoei - formol culture vaccine-microbial active 0.0 p; clostridium novyi type b - toxoid vaccine-toxoid active 0.0 p; clostridium perfringens type d toxoid vaccine-toxoid active 0.0 p; clostridium septicum - toxoid vaccine-toxoid active 0.0 p; clostridium tetani - toxoid vaccine-toxoid active 0.0 p; corynebacterium pseudotuberculosis (ovis) - toxoid vaccine-toxoid active 0.0 p; thiomersal mercury other 0.1 mg/ml - immunotherapy - lamb | sheep | ewe | hogget | lamb | ovine | ram | weaner | wether - black disease | blackleg | cheesy gland | enterotoxaemia (pulpy kidney) | malignant oedema | tetanus | white muscle disease | clostridium perfringens type d | lymphadenitis | lymphangitis | selenium deficiency | stiff lamb disease | subacute enzootic muscular dys | tetanus vaccination

GLANVAC 3S VACCINE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

glanvac 3s vaccine

zoetis australia pty ltd - selenium as sodium selenate; clostridium perfringens type d toxoid; clostridium tetani - toxoid; corynebacterium pseudotuberculosis (ovis) - toxoid; thiomersal - misc. vaccines or anti sera - selenium as sodium selenate mineral-selenium active 1.0 mg/ml; clostridium perfringens type d toxoid vaccine-toxoid active 0.0 undefined; clostridium tetani - toxoid vaccine-toxoid active 0.0 undefined; corynebacterium pseudotuberculosis (ovis) - toxoid vaccine-toxoid active 0.0 undefined; thiomersal mercury other 0.1 mg/ml - immunotherapy - lamb | sheep | ewe | hogget | lamb | ovine | ram | weaner | wether - caseous lymphadenitis (cheesy gland) | enterotoxaemia (pulpy kidney) | tetanus | white muscle disease | clostridium perfringens type d | selenium deficiency | stiff lamb disease | subacute enzootic muscular dys | tetanus vaccination

ULTRAVAC 5 IN 1 S WITH SELENIUM FOR LAMBS VACCINE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ultravac 5 in 1 s with selenium for lambs vaccine

zoetis australia pty ltd - thiomersal; selenium; clostridium chauvoei - toxoid; clostridium novyi type b - toxoid; clostridium perfringens type d toxoid; clostridium septicum - toxoid; tetanus = clostridium tetani - parenteral liquid/solution/suspension - thiomersal mercury active 0.1 mg/ml; selenium mineral-selenium active 1.0 mg/ml; clostridium chauvoei - toxoid vaccine-toxoid active 0.0 p; clostridium novyi type b - toxoid vaccine-toxoid active 0.0 p; clostridium perfringens type d toxoid vaccine-toxoid active 0.0 p; clostridium septicum - toxoid vaccine-toxoid active 0.0 p; tetanus = clostridium tetani vaccine-toxoid active 0.0 p - immunotherapy - lamb | sheep | ewe | hogget | lamb | ovine | ram | weaner | wether - black disease | blackleg | enterotoxaemia (pulpy kidney) | malignant oedema | tetanus | white muscle disease | clostridium perfringens type d | selenium deficiency | stiff lamb disease | subacute enzootic muscular dys | tetanus vaccination

VAXALL BOTULINUM TYPE D VACCINE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vaxall botulinum type d vaccine

fort dodge australia pty limited - clostridium botulinum type d toxoid - immunotherapy - cattle | sheep | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ewe | heifer | h - not applicable (vet)

VAXALL BOTULINUM TYPE C VACCINE FOR SHEEP AND CATTLE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vaxall botulinum type c vaccine for sheep and cattle

fort dodge australia pty limited - clostridium botulinum type c - immunotherapy - cattle | sheep | beef | bos indicus | bos taurus | bovine | buffalo | bull | bullock | calf | cow | dairy cow | ewe | heifer | h - not applicable (vet)

Netvax European Union - English - EMA (European Medicines Agency)

netvax

intervet international bv - clostridium-perfringens-type-a alpha toxoid - immunologicals for aves - chicken - for the active immunisation of chickens to provide passive immunisation against necrotic enteritis to their progeny, during the laying period.to reduce mortality and the incidence and severity of lesions caused by clostridium-perfringens-type-a-induced necrotic enteritis. efficacy was demonstrated by challenge of chicks approximately three weeks after hatching.the onset of passive transfer of immunity: 6 weeks following completion of the vaccination procedure.the duration of passive transfer of immunity: 51 weeks following completion of the vaccination procedure.